nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—SLC47A1—Ritonavir—acquired immunodeficiency syndrome	0.106	0.154	CbGbCtD
Sirolimus—SLCO1B1—Indinavir—acquired immunodeficiency syndrome	0.0348	0.0505	CbGbCtD
Sirolimus—SLCO1B1—Nelfinavir—acquired immunodeficiency syndrome	0.0338	0.0491	CbGbCtD
Sirolimus—SLCO1B1—Saquinavir—acquired immunodeficiency syndrome	0.0305	0.0444	CbGbCtD
Sirolimus—SLCO1B1—Ritonavir—acquired immunodeficiency syndrome	0.0305	0.0444	CbGbCtD
Sirolimus—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0236	0.0343	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0236	0.0343	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.0204	0.0297	CbGbCtD
Sirolimus—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.0204	0.0297	CbGbCtD
Sirolimus—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.0198	0.0288	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.0198	0.0288	CbGbCtD
Sirolimus—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0196	0.0285	CbGbCtD
Sirolimus—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.0179	0.026	CbGbCtD
Sirolimus—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.0179	0.026	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.0179	0.026	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.0179	0.026	CbGbCtD
Sirolimus—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0177	0.0258	CbGbCtD
Sirolimus—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0177	0.0258	CbGbCtD
Sirolimus—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0153	0.0222	CbGbCtD
Sirolimus—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0149	0.0216	CbGbCtD
Sirolimus—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0134	0.0195	CbGbCtD
Sirolimus—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0134	0.0195	CbGbCtD
Sirolimus—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0128	0.0185	CbGbCtD
Sirolimus—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0115	0.0168	CbGbCtD
Sirolimus—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00996	0.0145	CbGbCtD
Sirolimus—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00967	0.0141	CbGbCtD
Sirolimus—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00875	0.0127	CbGbCtD
Sirolimus—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00875	0.0127	CbGbCtD
Sirolimus—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00838	0.0122	CbGbCtD
Sirolimus—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00813	0.0118	CbGbCtD
Sirolimus—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00765	0.0111	CbGbCtD
Sirolimus—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00765	0.0111	CbGbCtD
Sirolimus—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00691	0.01	CbGbCtD
Sirolimus—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00691	0.01	CbGbCtD
Sirolimus—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00649	0.00943	CbGbCtD
Sirolimus—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00597	0.00867	CbGbCtD
Sirolimus—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00579	0.00842	CbGbCtD
Sirolimus—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00524	0.00761	CbGbCtD
Sirolimus—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00524	0.00761	CbGbCtD
Sirolimus—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00502	0.0073	CbGbCtD
Sirolimus—EIF4E—lymphoid tissue—acquired immunodeficiency syndrome	0.00241	0.0404	CbGeAlD
Sirolimus—MTOR—blood plasma—acquired immunodeficiency syndrome	0.00239	0.0401	CbGeAlD
Sirolimus—EIF4E—digestive system—acquired immunodeficiency syndrome	0.00238	0.0399	CbGeAlD
Sirolimus—EIF4E—blood—acquired immunodeficiency syndrome	0.00226	0.038	CbGeAlD
Sirolimus—FKBP1A—blood plasma—acquired immunodeficiency syndrome	0.00215	0.0361	CbGeAlD
Sirolimus—EIF4E—lung—acquired immunodeficiency syndrome	0.00199	0.0333	CbGeAlD
Sirolimus—EIF4E—nervous system—acquired immunodeficiency syndrome	0.00184	0.0308	CbGeAlD
Sirolimus—SLCO1B1—blood plasma—acquired immunodeficiency syndrome	0.00183	0.0306	CbGeAlD
Sirolimus—EIF4E—central nervous system—acquired immunodeficiency syndrome	0.00177	0.0297	CbGeAlD
Sirolimus—EIF4E—brain—acquired immunodeficiency syndrome	0.00141	0.0236	CbGeAlD
Sirolimus—FGF2—spinal cord—acquired immunodeficiency syndrome	0.00133	0.0223	CbGeAlD
Sirolimus—MTOR—retina—acquired immunodeficiency syndrome	0.00131	0.022	CbGeAlD
Sirolimus—FGF2—vagina—acquired immunodeficiency syndrome	0.00128	0.0215	CbGeAlD
Sirolimus—FGF2—lung—acquired immunodeficiency syndrome	0.00121	0.0203	CbGeAlD
Sirolimus—FKBP1A—retina—acquired immunodeficiency syndrome	0.00118	0.0198	CbGeAlD
Sirolimus—MTOR—skin of body—acquired immunodeficiency syndrome	0.00115	0.0193	CbGeAlD
Sirolimus—FKBP1A—skin of body—acquired immunodeficiency syndrome	0.00103	0.0173	CbGeAlD
Sirolimus—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000937	0.0157	CbGeAlD
Sirolimus—MTOR—lymphoid tissue—acquired immunodeficiency syndrome	0.000931	0.0156	CbGeAlD
Sirolimus—MTOR—digestive system—acquired immunodeficiency syndrome	0.00092	0.0154	CbGeAlD
Sirolimus—MTOR—blood—acquired immunodeficiency syndrome	0.000876	0.0147	CbGeAlD
Sirolimus—FGF2—brain—acquired immunodeficiency syndrome	0.000857	0.0144	CbGeAlD
Sirolimus—MTOR—bone marrow—acquired immunodeficiency syndrome	0.000848	0.0142	CbGeAlD
Sirolimus—MTOR—spinal cord—acquired immunodeficiency syndrome	0.000844	0.0142	CbGeAlD
Sirolimus—FKBP1A—lymphoid tissue—acquired immunodeficiency syndrome	0.000837	0.014	CbGeAlD
Sirolimus—FGF2—lymph node—acquired immunodeficiency syndrome	0.000828	0.0139	CbGeAlD
Sirolimus—FKBP1A—digestive system—acquired immunodeficiency syndrome	0.000827	0.0139	CbGeAlD
Sirolimus—MTOR—vagina—acquired immunodeficiency syndrome	0.000812	0.0136	CbGeAlD
Sirolimus—FKBP1A—blood—acquired immunodeficiency syndrome	0.000788	0.0132	CbGeAlD
Sirolimus—MTOR—lung—acquired immunodeficiency syndrome	0.000768	0.0129	CbGeAlD
Sirolimus—FKBP1A—bone marrow—acquired immunodeficiency syndrome	0.000762	0.0128	CbGeAlD
Sirolimus—FKBP1A—spinal cord—acquired immunodeficiency syndrome	0.000759	0.0127	CbGeAlD
Sirolimus—FKBP1A—vagina—acquired immunodeficiency syndrome	0.00073	0.0122	CbGeAlD
Sirolimus—MTOR—nervous system—acquired immunodeficiency syndrome	0.000711	0.0119	CbGeAlD
Sirolimus—SLC47A1—digestive system—acquired immunodeficiency syndrome	0.000711	0.0119	CbGeAlD
Sirolimus—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000703	0.0118	CbGeAlD
Sirolimus—SLCO1B1—digestive system—acquired immunodeficiency syndrome	0.000702	0.0118	CbGeAlD
Sirolimus—FKBP1A—lung—acquired immunodeficiency syndrome	0.000691	0.0116	CbGeAlD
Sirolimus—MTOR—central nervous system—acquired immunodeficiency syndrome	0.000685	0.0115	CbGeAlD
Sirolimus—SLC47A1—blood—acquired immunodeficiency syndrome	0.000677	0.0114	CbGeAlD
Sirolimus—SLCO1B1—blood—acquired immunodeficiency syndrome	0.000669	0.0112	CbGeAlD
Sirolimus—SLC47A1—spinal cord—acquired immunodeficiency syndrome	0.000652	0.0109	CbGeAlD
Sirolimus—FKBP1A—nervous system—acquired immunodeficiency syndrome	0.00064	0.0107	CbGeAlD
Sirolimus—SLC47A1—vagina—acquired immunodeficiency syndrome	0.000628	0.0105	CbGeAlD
Sirolimus—FKBP1A—central nervous system—acquired immunodeficiency syndrome	0.000616	0.0103	CbGeAlD
Sirolimus—SLC47A1—lung—acquired immunodeficiency syndrome	0.000594	0.00996	CbGeAlD
Sirolimus—SLC47A1—nervous system—acquired immunodeficiency syndrome	0.00055	0.00922	CbGeAlD
Sirolimus—MTOR—brain—acquired immunodeficiency syndrome	0.000544	0.00912	CbGeAlD
Sirolimus—SLC47A1—central nervous system—acquired immunodeficiency syndrome	0.000529	0.00888	CbGeAlD
Sirolimus—MTOR—lymph node—acquired immunodeficiency syndrome	0.000525	0.00881	CbGeAlD
Sirolimus—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000498	0.00834	CbGeAlD
Sirolimus—FKBP1A—brain—acquired immunodeficiency syndrome	0.000489	0.0082	CbGeAlD
Sirolimus—FKBP1A—lymph node—acquired immunodeficiency syndrome	0.000472	0.00792	CbGeAlD
Sirolimus—SLC47A1—brain—acquired immunodeficiency syndrome	0.00042	0.00705	CbGeAlD
Sirolimus—SLC47A1—lymph node—acquired immunodeficiency syndrome	0.000406	0.00681	CbGeAlD
Sirolimus—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.00036	0.00604	CbGeAlD
Sirolimus—CYP3A5—blood—acquired immunodeficiency syndrome	0.000343	0.00575	CbGeAlD
Sirolimus—Tacrolimus—ALB—acquired immunodeficiency syndrome	0.000324	1	CrCbGaD
Sirolimus—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000318	0.00533	CbGeAlD
Sirolimus—CYP3A5—lung—acquired immunodeficiency syndrome	0.000301	0.00504	CbGeAlD
Sirolimus—ABCB1—retina—acquired immunodeficiency syndrome	0.000272	0.00457	CbGeAlD
Sirolimus—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.00027	0.00453	CbGeAlD
Sirolimus—CYP3A4—blood—acquired immunodeficiency syndrome	0.000258	0.00432	CbGeAlD
Sirolimus—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000209	0.00351	CbGeAlD
Sirolimus—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000201	0.00337	CbGeAlD
Sirolimus—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000194	0.00325	CbGeAlD
Sirolimus—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000191	0.00321	CbGeAlD
Sirolimus—ABCB1—blood—acquired immunodeficiency syndrome	0.000182	0.00306	CbGeAlD
Sirolimus—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000176	0.00296	CbGeAlD
Sirolimus—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000176	0.00294	CbGeAlD
Sirolimus—ABCB1—vagina—acquired immunodeficiency syndrome	0.000169	0.00283	CbGeAlD
Sirolimus—ABCB1—lung—acquired immunodeficiency syndrome	0.00016	0.00268	CbGeAlD
Sirolimus—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000148	0.00248	CbGeAlD
Sirolimus—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000142	0.00239	CbGeAlD
Sirolimus—EIF4E—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000134	0.00508	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	0.000132	0.005	CbGpPWpGaD
Sirolimus—FGF2—Angiopoietin receptor Tie2-mediated signaling—TNF—acquired immunodeficiency syndrome	0.000129	0.00488	CbGpPWpGaD
Sirolimus—MTOR—IL12-mediated signaling events—IFNG—acquired immunodeficiency syndrome	0.000128	0.00483	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—CCNT1—acquired immunodeficiency syndrome	0.000125	0.00474	CbGpPWpGaD
Sirolimus—MTOR—IL12-mediated signaling events—CD4—acquired immunodeficiency syndrome	0.000123	0.00467	CbGpPWpGaD
Sirolimus—EIF4E—IRS-mediated signalling—IL6—acquired immunodeficiency syndrome	0.000122	0.00463	CbGpPWpGaD
Sirolimus—FGF2—Cardiac Hypertrophic Response—TNF—acquired immunodeficiency syndrome	0.000119	0.00452	CbGpPWpGaD
Sirolimus—EIF4E—IRS-related events—IL6—acquired immunodeficiency syndrome	0.000119	0.0045	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	0.000118	0.00446	CbGpPWpGaD
Sirolimus—EIF4E—IRS-related events triggered by IGF1R—IL6—acquired immunodeficiency syndrome	0.000118	0.00446	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	0.000117	0.00444	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—HLA-B—acquired immunodeficiency syndrome	0.000117	0.00443	CbGpPWpGaD
Sirolimus—MTOR—Regulation of Telomerase—IFNG—acquired immunodeficiency syndrome	0.000115	0.00437	CbGpPWpGaD
Sirolimus—FGF2—FRS2-mediated cascade—IL6—acquired immunodeficiency syndrome	0.000115	0.00436	CbGpPWpGaD
Sirolimus—EIF4E—Insulin receptor signalling cascade—IL6—acquired immunodeficiency syndrome	0.000115	0.00435	CbGpPWpGaD
Sirolimus—EIF4E—IGF1R signaling cascade—IL6—acquired immunodeficiency syndrome	0.000115	0.00435	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	0.000114	0.00432	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	0.000114	0.00432	CbGpPWpGaD
Sirolimus—MTOR—IL12-mediated signaling events—IL2—acquired immunodeficiency syndrome	0.000113	0.00429	CbGpPWpGaD
Sirolimus—ABCB1—brain—acquired immunodeficiency syndrome	0.000113	0.0019	CbGeAlD
Sirolimus—MTOR—Costimulation by the CD28 family—CD4—acquired immunodeficiency syndrome	0.000112	0.00422	CbGpPWpGaD
Sirolimus—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000109	0.00183	CbGeAlD
Sirolimus—EIF4E—Immune System—ACTG1—acquired immunodeficiency syndrome	0.000109	0.00413	CbGpPWpGaD
Sirolimus—FGF2—Differentiation Pathway—IL6—acquired immunodeficiency syndrome	0.000107	0.00407	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	0.000104	0.00394	CbGpPWpGaD
Sirolimus—SLC47A1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	0.000104	0.00394	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—CD79A—acquired immunodeficiency syndrome	0.000104	0.00393	CbGpPWpGaD
Sirolimus—MTOR—Regulation of Telomerase—IL2—acquired immunodeficiency syndrome	0.000103	0.00388	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.0001	0.0038	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	9.9e-05	0.00375	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	9.86e-05	0.00373	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	9.7e-05	0.00367	CbGpPWpGaD
Sirolimus—EIF4E—Signaling by Insulin receptor—IL6—acquired immunodeficiency syndrome	9.54e-05	0.00361	CbGpPWpGaD
Sirolimus—MTOR—CXCR4-mediated signaling events—CD4—acquired immunodeficiency syndrome	9.42e-05	0.00356	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—IFNG—acquired immunodeficiency syndrome	9.02e-05	0.00342	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—MBL2—acquired immunodeficiency syndrome	8.97e-05	0.0034	CbGpPWpGaD
Sirolimus—MTOR—Cardiac Hypertrophic Response—TNF—acquired immunodeficiency syndrome	8.86e-05	0.00335	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—HLA-B—acquired immunodeficiency syndrome	8.69e-05	0.00329	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—MBL2—acquired immunodeficiency syndrome	8.56e-05	0.00324	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	8.55e-05	0.00324	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CCNT1—acquired immunodeficiency syndrome	8.53e-05	0.00323	CbGpPWpGaD
Sirolimus—FGF2—MicroRNAs in cardiomyocyte hypertrophy—TNF—acquired immunodeficiency syndrome	8.51e-05	0.00322	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—acquired immunodeficiency syndrome	8.16e-05	0.00309	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.14e-05	0.00308	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.14e-05	0.00308	CbGpPWpGaD
Sirolimus—MTOR—TSLP Signaling Pathway—IL6—acquired immunodeficiency syndrome	8.11e-05	0.00307	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—IL2—acquired immunodeficiency syndrome	8.02e-05	0.00303	CbGpPWpGaD
Sirolimus—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	7.79e-05	0.000345	CcSEcCtD
Sirolimus—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	7.79e-05	0.000345	CcSEcCtD
Sirolimus—Tremor—Lamivudine—acquired immunodeficiency syndrome	7.78e-05	0.000345	CcSEcCtD
Sirolimus—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	7.77e-05	0.000345	CcSEcCtD
Sirolimus—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	7.76e-05	0.000344	CcSEcCtD
Sirolimus—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	7.75e-05	0.000344	CcSEcCtD
Sirolimus—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	7.75e-05	0.000344	CcSEcCtD
Sirolimus—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	7.74e-05	0.000343	CcSEcCtD
Sirolimus—MTOR—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	7.73e-05	0.00293	CbGpPWpGaD
Sirolimus—Pruritus—Stavudine—acquired immunodeficiency syndrome	7.72e-05	0.000343	CcSEcCtD
Sirolimus—Asthenia—Abacavir—acquired immunodeficiency syndrome	7.72e-05	0.000342	CcSEcCtD
Sirolimus—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	7.71e-05	0.000342	CcSEcCtD
Sirolimus—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	7.7e-05	0.000342	CcSEcCtD
Sirolimus—Chest pain—Ritonavir—acquired immunodeficiency syndrome	7.7e-05	0.000341	CcSEcCtD
Sirolimus—Myalgia—Ritonavir—acquired immunodeficiency syndrome	7.7e-05	0.000341	CcSEcCtD
Sirolimus—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	7.7e-05	0.000341	CcSEcCtD
Sirolimus—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	7.67e-05	0.00034	CcSEcCtD
Sirolimus—Anaemia—Lamivudine—acquired immunodeficiency syndrome	7.67e-05	0.00034	CcSEcCtD
Sirolimus—Anxiety—Ritonavir—acquired immunodeficiency syndrome	7.67e-05	0.00034	CcSEcCtD
Sirolimus—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	7.65e-05	0.000339	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	7.64e-05	0.000339	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	7.62e-05	0.000338	CcSEcCtD
Sirolimus—Pruritus—Abacavir—acquired immunodeficiency syndrome	7.61e-05	0.000338	CcSEcCtD
Sirolimus—Anorexia—Delavirdine—acquired immunodeficiency syndrome	7.61e-05	0.000337	CcSEcCtD
Sirolimus—Discomfort—Ritonavir—acquired immunodeficiency syndrome	7.6e-05	0.000337	CcSEcCtD
Sirolimus—FGF2—Disease—APOBEC3G—acquired immunodeficiency syndrome	7.6e-05	0.00288	CbGpPWpGaD
Sirolimus—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	7.6e-05	0.000337	CcSEcCtD
Sirolimus—Cough—Saquinavir—acquired immunodeficiency syndrome	7.59e-05	0.000337	CcSEcCtD
Sirolimus—Angioedema—Lamivudine—acquired immunodeficiency syndrome	7.58e-05	0.000336	CcSEcCtD
Sirolimus—Pain—Indinavir—acquired immunodeficiency syndrome	7.55e-05	0.000335	CcSEcCtD
Sirolimus—Constipation—Indinavir—acquired immunodeficiency syndrome	7.55e-05	0.000335	CcSEcCtD
Sirolimus—Insomnia—Efavirenz—acquired immunodeficiency syndrome	7.54e-05	0.000335	CcSEcCtD
Sirolimus—Hypertension—Saquinavir—acquired immunodeficiency syndrome	7.51e-05	0.000333	CcSEcCtD
Sirolimus—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	7.5e-05	0.000333	CcSEcCtD
Sirolimus—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	7.5e-05	0.000333	CcSEcCtD
Sirolimus—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	7.5e-05	0.00284	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	7.5e-05	0.00284	CbGpPWpGaD
Sirolimus—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	7.49e-05	0.000332	CcSEcCtD
Sirolimus—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	7.49e-05	0.000332	CcSEcCtD
Sirolimus—Malaise—Lamivudine—acquired immunodeficiency syndrome	7.49e-05	0.000332	CcSEcCtD
Sirolimus—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	7.47e-05	0.000331	CcSEcCtD
Sirolimus—Nausea—Didanosine—acquired immunodeficiency syndrome	7.47e-05	0.000331	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.47e-05	0.00283	CbGpPWpGaD
Sirolimus—Hypotension—Delavirdine—acquired immunodeficiency syndrome	7.46e-05	0.000331	CcSEcCtD
Sirolimus—Syncope—Lamivudine—acquired immunodeficiency syndrome	7.44e-05	0.00033	CcSEcCtD
Sirolimus—Confusional state—Ritonavir—acquired immunodeficiency syndrome	7.44e-05	0.00033	CcSEcCtD
Sirolimus—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	7.43e-05	0.00033	CcSEcCtD
Sirolimus—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	7.43e-05	0.00033	CcSEcCtD
Sirolimus—Somnolence—Efavirenz—acquired immunodeficiency syndrome	7.41e-05	0.000329	CcSEcCtD
Sirolimus—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	7.41e-05	0.000329	CcSEcCtD
Sirolimus—Chest pain—Saquinavir—acquired immunodeficiency syndrome	7.41e-05	0.000329	CcSEcCtD
Sirolimus—Myalgia—Saquinavir—acquired immunodeficiency syndrome	7.41e-05	0.000329	CcSEcCtD
Sirolimus—Anxiety—Saquinavir—acquired immunodeficiency syndrome	7.38e-05	0.000327	CcSEcCtD
Sirolimus—Oedema—Ritonavir—acquired immunodeficiency syndrome	7.38e-05	0.000327	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.36e-05	0.00279	CbGpPWpGaD
Sirolimus—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	7.36e-05	0.000326	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	7.36e-05	0.000326	CcSEcCtD
Sirolimus—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	7.34e-05	0.000326	CcSEcCtD
Sirolimus—Discomfort—Saquinavir—acquired immunodeficiency syndrome	7.32e-05	0.000325	CcSEcCtD
Sirolimus—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	7.3e-05	0.00276	CbGpPWpGaD
Sirolimus—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	7.3e-05	0.000324	CcSEcCtD
Sirolimus—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	7.27e-05	0.000323	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	7.27e-05	0.000322	CcSEcCtD
Sirolimus—Shock—Ritonavir—acquired immunodeficiency syndrome	7.26e-05	0.000322	CcSEcCtD
Sirolimus—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	7.25e-05	0.000322	CcSEcCtD
Sirolimus—Cough—Lamivudine—acquired immunodeficiency syndrome	7.24e-05	0.000321	CcSEcCtD
Sirolimus—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	7.24e-05	0.000321	CcSEcCtD
Sirolimus—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	7.24e-05	0.000321	CcSEcCtD
Sirolimus—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	7.22e-05	0.00032	CcSEcCtD
Sirolimus—Dizziness—Stavudine—acquired immunodeficiency syndrome	7.22e-05	0.00032	CcSEcCtD
Sirolimus—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	7.22e-05	0.00032	CcSEcCtD
Sirolimus—Insomnia—Delavirdine—acquired immunodeficiency syndrome	7.22e-05	0.00032	CcSEcCtD
Sirolimus—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	7.2e-05	0.000319	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	7.2e-05	0.000319	CcSEcCtD
Sirolimus—Vomiting—Nevirapine—acquired immunodeficiency syndrome	7.19e-05	0.000319	CcSEcCtD
Sirolimus—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	7.17e-05	0.000318	CcSEcCtD
Sirolimus—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	7.16e-05	0.000318	CcSEcCtD
Sirolimus—Confusional state—Saquinavir—acquired immunodeficiency syndrome	7.16e-05	0.000318	CcSEcCtD
Sirolimus—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	7.13e-05	0.0027	CbGpPWpGaD
Sirolimus—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	7.13e-05	0.000316	CcSEcCtD
Sirolimus—Pain—Efavirenz—acquired immunodeficiency syndrome	7.13e-05	0.000316	CcSEcCtD
Sirolimus—Constipation—Efavirenz—acquired immunodeficiency syndrome	7.13e-05	0.000316	CcSEcCtD
Sirolimus—Rash—Nevirapine—acquired immunodeficiency syndrome	7.13e-05	0.000316	CcSEcCtD
Sirolimus—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	7.12e-05	0.000316	CcSEcCtD
Sirolimus—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	7.11e-05	0.000315	CcSEcCtD
Sirolimus—Dizziness—Abacavir—acquired immunodeficiency syndrome	7.11e-05	0.000315	CcSEcCtD
Sirolimus—Oedema—Saquinavir—acquired immunodeficiency syndrome	7.1e-05	0.000315	CcSEcCtD
Sirolimus—Somnolence—Delavirdine—acquired immunodeficiency syndrome	7.09e-05	0.000315	CcSEcCtD
Sirolimus—Headache—Nevirapine—acquired immunodeficiency syndrome	7.08e-05	0.000314	CcSEcCtD
Sirolimus—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	7.07e-05	0.000313	CcSEcCtD
Sirolimus—Chest pain—Lamivudine—acquired immunodeficiency syndrome	7.07e-05	0.000313	CcSEcCtD
Sirolimus—Myalgia—Lamivudine—acquired immunodeficiency syndrome	7.07e-05	0.000313	CcSEcCtD
Sirolimus—Infection—Saquinavir—acquired immunodeficiency syndrome	7.05e-05	0.000313	CcSEcCtD
Sirolimus—Anxiety—Lamivudine—acquired immunodeficiency syndrome	7.04e-05	0.000312	CcSEcCtD
Sirolimus—EIF4E—Immune System—CCR2—acquired immunodeficiency syndrome	7.03e-05	0.00266	CbGpPWpGaD
Sirolimus—Anorexia—Ritonavir—acquired immunodeficiency syndrome	7.03e-05	0.000312	CcSEcCtD
Sirolimus—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	7.02e-05	0.000311	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	7.02e-05	0.000311	CcSEcCtD
Sirolimus—Shock—Saquinavir—acquired immunodeficiency syndrome	6.99e-05	0.00031	CcSEcCtD
Sirolimus—Discomfort—Lamivudine—acquired immunodeficiency syndrome	6.98e-05	0.00031	CcSEcCtD
Sirolimus—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	6.98e-05	0.000309	CcSEcCtD
Sirolimus—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	6.98e-05	0.000309	CcSEcCtD
Sirolimus—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	6.96e-05	0.000309	CcSEcCtD
Sirolimus—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	6.96e-05	0.000309	CcSEcCtD
Sirolimus—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	6.95e-05	0.000308	CcSEcCtD
Sirolimus—Vomiting—Stavudine—acquired immunodeficiency syndrome	6.94e-05	0.000308	CcSEcCtD
Sirolimus—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	6.94e-05	0.000308	CcSEcCtD
Sirolimus—Rash—Nelfinavir—acquired immunodeficiency syndrome	6.91e-05	0.000306	CcSEcCtD
Sirolimus—FKBP1A—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	6.9e-05	0.00261	CbGpPWpGaD
Sirolimus—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	6.9e-05	0.000306	CcSEcCtD
Sirolimus—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	6.9e-05	0.000306	CcSEcCtD
Sirolimus—Hypotension—Ritonavir—acquired immunodeficiency syndrome	6.89e-05	0.000306	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	6.89e-05	0.000306	CcSEcCtD
Sirolimus—Rash—Stavudine—acquired immunodeficiency syndrome	6.88e-05	0.000305	CcSEcCtD
Sirolimus—Dermatitis—Stavudine—acquired immunodeficiency syndrome	6.88e-05	0.000305	CcSEcCtD
Sirolimus—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	6.87e-05	0.000305	CcSEcCtD
Sirolimus—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	6.86e-05	0.000304	CcSEcCtD
Sirolimus—Headache—Nelfinavir—acquired immunodeficiency syndrome	6.86e-05	0.000304	CcSEcCtD
Sirolimus—Headache—Stavudine—acquired immunodeficiency syndrome	6.84e-05	0.000303	CcSEcCtD
Sirolimus—Vomiting—Abacavir—acquired immunodeficiency syndrome	6.84e-05	0.000303	CcSEcCtD
Sirolimus—Confusional state—Lamivudine—acquired immunodeficiency syndrome	6.83e-05	0.000303	CcSEcCtD
Sirolimus—Constipation—Delavirdine—acquired immunodeficiency syndrome	6.82e-05	0.000303	CcSEcCtD
Sirolimus—Pain—Delavirdine—acquired immunodeficiency syndrome	6.82e-05	0.000303	CcSEcCtD
Sirolimus—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	6.82e-05	0.000302	CcSEcCtD
Sirolimus—Asthenia—Zidovudine—acquired immunodeficiency syndrome	6.81e-05	0.000302	CcSEcCtD
Sirolimus—FGF2—IRS-mediated signalling—IL6—acquired immunodeficiency syndrome	6.8e-05	0.00257	CbGpPWpGaD
Sirolimus—Rash—Abacavir—acquired immunodeficiency syndrome	6.78e-05	0.000301	CcSEcCtD
Sirolimus—Dermatitis—Abacavir—acquired immunodeficiency syndrome	6.78e-05	0.000301	CcSEcCtD
Sirolimus—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	6.77e-05	0.0003	CcSEcCtD
Sirolimus—Oedema—Lamivudine—acquired immunodeficiency syndrome	6.77e-05	0.0003	CcSEcCtD
Sirolimus—Anorexia—Saquinavir—acquired immunodeficiency syndrome	6.77e-05	0.0003	CcSEcCtD
Sirolimus—Headache—Abacavir—acquired immunodeficiency syndrome	6.74e-05	0.000299	CcSEcCtD
Sirolimus—Infection—Lamivudine—acquired immunodeficiency syndrome	6.73e-05	0.000299	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	6.72e-05	0.000298	CcSEcCtD
Sirolimus—Nausea—Nevirapine—acquired immunodeficiency syndrome	6.72e-05	0.000298	CcSEcCtD
Sirolimus—Pruritus—Zidovudine—acquired immunodeficiency syndrome	6.71e-05	0.000298	CcSEcCtD
Sirolimus—FGF2—Innate Immune System—CCR2—acquired immunodeficiency syndrome	6.71e-05	0.00254	CbGpPWpGaD
Sirolimus—Insomnia—Ritonavir—acquired immunodeficiency syndrome	6.67e-05	0.000296	CcSEcCtD
Sirolimus—Shock—Lamivudine—acquired immunodeficiency syndrome	6.66e-05	0.000296	CcSEcCtD
Sirolimus—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	6.64e-05	0.000295	CcSEcCtD
Sirolimus—Hypotension—Saquinavir—acquired immunodeficiency syndrome	6.64e-05	0.000294	CcSEcCtD
Sirolimus—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	6.63e-05	0.000294	CcSEcCtD
Sirolimus—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	6.62e-05	0.000294	CcSEcCtD
Sirolimus—FGF2—IRS-related events—IL6—acquired immunodeficiency syndrome	6.61e-05	0.0025	CbGpPWpGaD
Sirolimus—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	6.59e-05	0.000292	CcSEcCtD
Sirolimus—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	6.59e-05	0.000292	CcSEcCtD
Sirolimus—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	6.58e-05	0.000292	CcSEcCtD
Sirolimus—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	6.58e-05	0.000292	CcSEcCtD
Sirolimus—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	6.57e-05	0.000292	CcSEcCtD
Sirolimus—Somnolence—Ritonavir—acquired immunodeficiency syndrome	6.56e-05	0.000291	CcSEcCtD
Sirolimus—FGF2—IRS-related events triggered by IGF1R—IL6—acquired immunodeficiency syndrome	6.55e-05	0.00248	CbGpPWpGaD
Sirolimus—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	6.55e-05	0.00029	CcSEcCtD
Sirolimus—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	6.52e-05	0.000289	CcSEcCtD
Sirolimus—Nausea—Nelfinavir—acquired immunodeficiency syndrome	6.51e-05	0.000289	CcSEcCtD
Sirolimus—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	6.5e-05	0.000288	CcSEcCtD
Sirolimus—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	6.49e-05	0.000288	CcSEcCtD
Sirolimus—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	6.49e-05	0.000288	CcSEcCtD
Sirolimus—Nausea—Stavudine—acquired immunodeficiency syndrome	6.49e-05	0.000288	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	6.47e-05	0.000287	CcSEcCtD
Sirolimus—FGF2—Disease—CCNT1—acquired immunodeficiency syndrome	6.46e-05	0.00245	CbGpPWpGaD
Sirolimus—Anorexia—Lamivudine—acquired immunodeficiency syndrome	6.46e-05	0.000286	CcSEcCtD
Sirolimus—Insomnia—Saquinavir—acquired immunodeficiency syndrome	6.42e-05	0.000285	CcSEcCtD
Sirolimus—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	6.41e-05	0.000284	CcSEcCtD
Sirolimus—Nausea—Abacavir—acquired immunodeficiency syndrome	6.39e-05	0.000283	CcSEcCtD
Sirolimus—FGF2—Insulin receptor signalling cascade—IL6—acquired immunodeficiency syndrome	6.38e-05	0.00242	CbGpPWpGaD
Sirolimus—FGF2—IGF1R signaling cascade—IL6—acquired immunodeficiency syndrome	6.38e-05	0.00242	CbGpPWpGaD
Sirolimus—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	6.38e-05	0.000283	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	6.37e-05	0.000283	CcSEcCtD
Sirolimus—MTOR—Innate Immune System—MBL2—acquired immunodeficiency syndrome	6.35e-05	0.0024	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IFNA1—acquired immunodeficiency syndrome	6.33e-05	0.0024	CbGpPWpGaD
Sirolimus—Asthenia—Indinavir—acquired immunodeficiency syndrome	6.33e-05	0.000281	CcSEcCtD
Sirolimus—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	6.33e-05	0.000281	CcSEcCtD
Sirolimus—Hypotension—Lamivudine—acquired immunodeficiency syndrome	6.33e-05	0.000281	CcSEcCtD
Sirolimus—Somnolence—Saquinavir—acquired immunodeficiency syndrome	6.31e-05	0.00028	CcSEcCtD
Sirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—acquired immunodeficiency syndrome	6.31e-05	0.00239	CbGpPWpGaD
Sirolimus—Constipation—Ritonavir—acquired immunodeficiency syndrome	6.31e-05	0.00028	CcSEcCtD
Sirolimus—Pain—Ritonavir—acquired immunodeficiency syndrome	6.31e-05	0.00028	CcSEcCtD
Sirolimus—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	6.31e-05	0.00028	CcSEcCtD
Sirolimus—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	6.31e-05	0.00028	CcSEcCtD
Sirolimus—Dizziness—Zidovudine—acquired immunodeficiency syndrome	6.28e-05	0.000278	CcSEcCtD
Sirolimus—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	6.25e-05	0.000277	CcSEcCtD
Sirolimus—Pruritus—Indinavir—acquired immunodeficiency syndrome	6.24e-05	0.000277	CcSEcCtD
Sirolimus—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	6.17e-05	0.000274	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	6.17e-05	0.000274	CcSEcCtD
Sirolimus—EIF4E—Immune System—CD79A—acquired immunodeficiency syndrome	6.15e-05	0.00233	CbGpPWpGaD
Sirolimus—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	6.14e-05	0.000272	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	6.13e-05	0.000272	CcSEcCtD
Sirolimus—Insomnia—Lamivudine—acquired immunodeficiency syndrome	6.13e-05	0.000272	CcSEcCtD
Sirolimus—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	6.08e-05	0.00027	CcSEcCtD
Sirolimus—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	6.08e-05	0.00027	CcSEcCtD
Sirolimus—Constipation—Saquinavir—acquired immunodeficiency syndrome	6.07e-05	0.000269	CcSEcCtD
Sirolimus—Pain—Saquinavir—acquired immunodeficiency syndrome	6.07e-05	0.000269	CcSEcCtD
Sirolimus—FGF2—Immune System—ACTG1—acquired immunodeficiency syndrome	6.07e-05	0.0023	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	6.04e-05	0.00229	CbGpPWpGaD
Sirolimus—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	6.04e-05	0.000268	CcSEcCtD
Sirolimus—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	6.04e-05	0.000268	CcSEcCtD
Sirolimus—Vomiting—Zidovudine—acquired immunodeficiency syndrome	6.03e-05	0.000268	CcSEcCtD
Sirolimus—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	6.03e-05	0.000268	CcSEcCtD
Sirolimus—Somnolence—Lamivudine—acquired immunodeficiency syndrome	6.02e-05	0.000267	CcSEcCtD
Sirolimus—Rash—Zidovudine—acquired immunodeficiency syndrome	5.98e-05	0.000265	CcSEcCtD
Sirolimus—Asthenia—Efavirenz—acquired immunodeficiency syndrome	5.98e-05	0.000265	CcSEcCtD
Sirolimus—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	5.98e-05	0.000265	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.97e-05	0.00226	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.97e-05	0.00226	CbGpPWpGaD
Sirolimus—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	5.96e-05	0.000264	CcSEcCtD
Sirolimus—Headache—Zidovudine—acquired immunodeficiency syndrome	5.95e-05	0.000264	CcSEcCtD
Sirolimus—Pruritus—Efavirenz—acquired immunodeficiency syndrome	5.9e-05	0.000262	CcSEcCtD
Sirolimus—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	5.89e-05	0.000261	CcSEcCtD
Sirolimus—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	5.88e-05	0.000261	CcSEcCtD
Sirolimus—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	5.85e-05	0.00026	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	5.85e-05	0.000259	CcSEcCtD
Sirolimus—Dizziness—Indinavir—acquired immunodeficiency syndrome	5.84e-05	0.000259	CcSEcCtD
Sirolimus—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	5.83e-05	0.000259	CcSEcCtD
Sirolimus—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	5.83e-05	0.000259	CcSEcCtD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	5.82e-05	0.0022	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	5.81e-05	0.000258	CcSEcCtD
Sirolimus—Constipation—Lamivudine—acquired immunodeficiency syndrome	5.79e-05	0.000257	CcSEcCtD
Sirolimus—Pain—Lamivudine—acquired immunodeficiency syndrome	5.79e-05	0.000257	CcSEcCtD
Sirolimus—Asthenia—Delavirdine—acquired immunodeficiency syndrome	5.72e-05	0.000254	CcSEcCtD
Sirolimus—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	5.71e-05	0.000253	CcSEcCtD
Sirolimus—Pruritus—Delavirdine—acquired immunodeficiency syndrome	5.64e-05	0.00025	CcSEcCtD
Sirolimus—MTOR—Disease—APOBEC3G—acquired immunodeficiency syndrome	5.64e-05	0.00213	CbGpPWpGaD
Sirolimus—Nausea—Zidovudine—acquired immunodeficiency syndrome	5.64e-05	0.00025	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	5.64e-05	0.00213	CbGpPWpGaD
Sirolimus—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	5.61e-05	0.000249	CcSEcCtD
Sirolimus—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	5.61e-05	0.000249	CcSEcCtD
Sirolimus—Vomiting—Indinavir—acquired immunodeficiency syndrome	5.61e-05	0.000249	CcSEcCtD
Sirolimus—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	5.58e-05	0.000248	CcSEcCtD
Sirolimus—Rash—Indinavir—acquired immunodeficiency syndrome	5.56e-05	0.000247	CcSEcCtD
Sirolimus—Dermatitis—Indinavir—acquired immunodeficiency syndrome	5.56e-05	0.000247	CcSEcCtD
Sirolimus—MTOR—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.54e-05	0.0021	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	5.54e-05	0.000246	CcSEcCtD
Sirolimus—Headache—Indinavir—acquired immunodeficiency syndrome	5.53e-05	0.000245	CcSEcCtD
Sirolimus—Dizziness—Efavirenz—acquired immunodeficiency syndrome	5.51e-05	0.000245	CcSEcCtD
Sirolimus—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	5.46e-05	0.000242	CcSEcCtD
Sirolimus—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	5.44e-05	0.000241	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.4e-05	0.00204	CbGpPWpGaD
Sirolimus—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	5.36e-05	0.000238	CcSEcCtD
Sirolimus—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	5.36e-05	0.000238	CcSEcCtD
Sirolimus—FGF2—Signaling by Insulin receptor—IL6—acquired immunodeficiency syndrome	5.3e-05	0.00201	CbGpPWpGaD
Sirolimus—Vomiting—Efavirenz—acquired immunodeficiency syndrome	5.3e-05	0.000235	CcSEcCtD
Sirolimus—Asthenia—Ritonavir—acquired immunodeficiency syndrome	5.29e-05	0.000235	CcSEcCtD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.29e-05	0.002	CbGpPWpGaD
Sirolimus—Dizziness—Delavirdine—acquired immunodeficiency syndrome	5.28e-05	0.000234	CcSEcCtD
Sirolimus—Rash—Efavirenz—acquired immunodeficiency syndrome	5.26e-05	0.000233	CcSEcCtD
Sirolimus—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	5.25e-05	0.000233	CcSEcCtD
Sirolimus—Nausea—Indinavir—acquired immunodeficiency syndrome	5.24e-05	0.000233	CcSEcCtD
Sirolimus—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	5.23e-05	0.000232	CcSEcCtD
Sirolimus—Headache—Efavirenz—acquired immunodeficiency syndrome	5.22e-05	0.000232	CcSEcCtD
Sirolimus—Pruritus—Ritonavir—acquired immunodeficiency syndrome	5.22e-05	0.000232	CcSEcCtD
Sirolimus—Asthenia—Saquinavir—acquired immunodeficiency syndrome	5.09e-05	0.000226	CcSEcCtD
Sirolimus—SLCO1B1—Metabolism—TAT—acquired immunodeficiency syndrome	5.08e-05	0.00192	CbGpPWpGaD
Sirolimus—Vomiting—Delavirdine—acquired immunodeficiency syndrome	5.07e-05	0.000225	CcSEcCtD
Sirolimus—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	5.05e-05	0.000224	CcSEcCtD
Sirolimus—MTOR—IRS-mediated signalling—IL6—acquired immunodeficiency syndrome	5.05e-05	0.00191	CbGpPWpGaD
Sirolimus—Rash—Delavirdine—acquired immunodeficiency syndrome	5.03e-05	0.000223	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.03e-05	0.0019	CbGpPWpGaD
Sirolimus—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	5.03e-05	0.000223	CcSEcCtD
Sirolimus—Pruritus—Saquinavir—acquired immunodeficiency syndrome	5.02e-05	0.000223	CcSEcCtD
Sirolimus—EIF4E—Immune System—CD40LG—acquired immunodeficiency syndrome	5.01e-05	0.0019	CbGpPWpGaD
Sirolimus—Headache—Delavirdine—acquired immunodeficiency syndrome	5e-05	0.000222	CcSEcCtD
Sirolimus—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	4.99e-05	0.000221	CcSEcCtD
Sirolimus—FGF2—Immune System—MBL2—acquired immunodeficiency syndrome	4.99e-05	0.00189	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CCR2—acquired immunodeficiency syndrome	4.98e-05	0.00189	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD8A—acquired immunodeficiency syndrome	4.96e-05	0.00188	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CSF2—acquired immunodeficiency syndrome	4.96e-05	0.00188	CbGpPWpGaD
Sirolimus—Nausea—Efavirenz—acquired immunodeficiency syndrome	4.95e-05	0.00022	CcSEcCtD
Sirolimus—MTOR—IRS-related events—IL6—acquired immunodeficiency syndrome	4.91e-05	0.00186	CbGpPWpGaD
Sirolimus—Dizziness—Ritonavir—acquired immunodeficiency syndrome	4.88e-05	0.000216	CcSEcCtD
Sirolimus—MTOR—IRS-related events triggered by IGF1R—IL6—acquired immunodeficiency syndrome	4.86e-05	0.00184	CbGpPWpGaD
Sirolimus—Asthenia—Lamivudine—acquired immunodeficiency syndrome	4.86e-05	0.000216	CcSEcCtD
Sirolimus—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	4.86e-05	0.000216	CcSEcCtD
Sirolimus—MTOR—Disease—CCNT1—acquired immunodeficiency syndrome	4.8e-05	0.00181	CbGpPWpGaD
Sirolimus—Pruritus—Lamivudine—acquired immunodeficiency syndrome	4.79e-05	0.000213	CcSEcCtD
Sirolimus—EIF4E—Immune System—HLA-B—acquired immunodeficiency syndrome	4.77e-05	0.0018	CbGpPWpGaD
Sirolimus—Nausea—Delavirdine—acquired immunodeficiency syndrome	4.74e-05	0.00021	CcSEcCtD
Sirolimus—MTOR—IGF1R signaling cascade—IL6—acquired immunodeficiency syndrome	4.74e-05	0.00179	CbGpPWpGaD
Sirolimus—MTOR—Insulin receptor signalling cascade—IL6—acquired immunodeficiency syndrome	4.74e-05	0.00179	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	4.71e-05	0.00178	CbGpPWpGaD
Sirolimus—Dizziness—Saquinavir—acquired immunodeficiency syndrome	4.7e-05	0.000208	CcSEcCtD
Sirolimus—Vomiting—Ritonavir—acquired immunodeficiency syndrome	4.69e-05	0.000208	CcSEcCtD
Sirolimus—CYP3A7—Metabolism—TAT—acquired immunodeficiency syndrome	4.66e-05	0.00176	CbGpPWpGaD
Sirolimus—Rash—Ritonavir—acquired immunodeficiency syndrome	4.65e-05	0.000206	CcSEcCtD
Sirolimus—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	4.65e-05	0.000206	CcSEcCtD
Sirolimus—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	4.64e-05	0.000206	CcSEcCtD
Sirolimus—Headache—Ritonavir—acquired immunodeficiency syndrome	4.62e-05	0.000205	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	4.59e-05	0.00174	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	4.55e-05	0.00172	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.55e-05	0.00172	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	4.54e-05	0.00172	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	4.54e-05	0.00172	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.53e-05	0.00171	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.53e-05	0.00171	CbGpPWpGaD
Sirolimus—Vomiting—Saquinavir—acquired immunodeficiency syndrome	4.52e-05	0.0002	CcSEcCtD
Sirolimus—MTOR—Immune System—ACTG1—acquired immunodeficiency syndrome	4.5e-05	0.0017	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	4.49e-05	0.0017	CbGpPWpGaD
Sirolimus—Dizziness—Lamivudine—acquired immunodeficiency syndrome	4.48e-05	0.000199	CcSEcCtD
Sirolimus—FKBP1A—Disease—CXCR4—acquired immunodeficiency syndrome	4.48e-05	0.0017	CbGpPWpGaD
Sirolimus—Rash—Saquinavir—acquired immunodeficiency syndrome	4.48e-05	0.000199	CcSEcCtD
Sirolimus—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	4.47e-05	0.000198	CcSEcCtD
Sirolimus—Headache—Saquinavir—acquired immunodeficiency syndrome	4.45e-05	0.000197	CcSEcCtD
Sirolimus—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	4.41e-05	0.00167	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	4.41e-05	0.00167	CbGpPWpGaD
Sirolimus—Nausea—Ritonavir—acquired immunodeficiency syndrome	4.38e-05	0.000194	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	4.37e-05	0.00165	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	4.34e-05	0.00164	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AGPS—acquired immunodeficiency syndrome	4.32e-05	0.00163	CbGpPWpGaD
Sirolimus—Vomiting—Lamivudine—acquired immunodeficiency syndrome	4.31e-05	0.000191	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.28e-05	0.00162	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.28e-05	0.00162	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	4.27e-05	0.00162	CbGpPWpGaD
Sirolimus—Rash—Lamivudine—acquired immunodeficiency syndrome	4.27e-05	0.000189	CcSEcCtD
Sirolimus—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	4.27e-05	0.000189	CcSEcCtD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—IL6—acquired immunodeficiency syndrome	4.26e-05	0.00161	CbGpPWpGaD
Sirolimus—Headache—Lamivudine—acquired immunodeficiency syndrome	4.24e-05	0.000188	CcSEcCtD
Sirolimus—Nausea—Saquinavir—acquired immunodeficiency syndrome	4.22e-05	0.000187	CcSEcCtD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—acquired immunodeficiency syndrome	4.2e-05	0.00159	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	4.18e-05	0.00158	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.09e-05	0.00155	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	4.08e-05	0.00154	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	4.06e-05	0.00154	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	4.04e-05	0.00153	CbGpPWpGaD
Sirolimus—Nausea—Lamivudine—acquired immunodeficiency syndrome	4.02e-05	0.000178	CcSEcCtD
Sirolimus—FGF2—DAP12 signaling—IL6—acquired immunodeficiency syndrome	4.02e-05	0.00152	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AGPS—acquired immunodeficiency syndrome	3.96e-05	0.0015	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	3.96e-05	0.0015	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—IL6—acquired immunodeficiency syndrome	3.93e-05	0.00149	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	3.92e-05	0.00148	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CCR2—acquired immunodeficiency syndrome	3.91e-05	0.00148	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	3.78e-05	0.00143	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	3.78e-05	0.00143	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—IL6—acquired immunodeficiency syndrome	3.78e-05	0.00143	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	3.75e-05	0.00142	CbGpPWpGaD
Sirolimus—SLCO1B1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.72e-05	0.00141	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	3.71e-05	0.00141	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MBL2—acquired immunodeficiency syndrome	3.7e-05	0.0014	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	3.7e-05	0.0014	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.69e-05	0.0014	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IFNA1—acquired immunodeficiency syndrome	3.52e-05	0.00133	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD79A—acquired immunodeficiency syndrome	3.42e-05	0.00129	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	3.41e-05	0.00129	CbGpPWpGaD
Sirolimus—FGF2—Disease—CXCR4—acquired immunodeficiency syndrome	3.39e-05	0.00128	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	3.38e-05	0.00128	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	3.37e-05	0.00128	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TAT—acquired immunodeficiency syndrome	3.37e-05	0.00128	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	3.37e-05	0.00127	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.36e-05	0.00127	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.36e-05	0.00127	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	3.35e-05	0.00127	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.34e-05	0.00126	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.25e-05	0.00123	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	3.24e-05	0.00123	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	3.22e-05	0.00122	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.2e-05	0.00121	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	3.17e-05	0.0012	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.14e-05	0.00119	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.14e-05	0.00119	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CCR5—acquired immunodeficiency syndrome	3.07e-05	0.00116	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.04e-05	0.00115	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	3.03e-05	0.00115	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	3.01e-05	0.00114	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	3e-05	0.00113	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—IL6—acquired immunodeficiency syndrome	2.98e-05	0.00113	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IFNG—acquired immunodeficiency syndrome	2.95e-05	0.00112	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.93e-05	0.00111	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CCR2—acquired immunodeficiency syndrome	2.9e-05	0.0011	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	2.87e-05	0.00108	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	2.85e-05	0.00108	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD4—acquired immunodeficiency syndrome	2.85e-05	0.00108	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	2.81e-05	0.00106	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—IL6—acquired immunodeficiency syndrome	2.81e-05	0.00106	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	2.81e-05	0.00106	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.8e-05	0.00106	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD40LG—acquired immunodeficiency syndrome	2.79e-05	0.00105	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	2.78e-05	0.00105	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	2.76e-05	0.00104	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CSF2—acquired immunodeficiency syndrome	2.76e-05	0.00104	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD8A—acquired immunodeficiency syndrome	2.76e-05	0.00104	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	2.74e-05	0.00104	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CD4—acquired immunodeficiency syndrome	2.72e-05	0.00103	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HLA-B—acquired immunodeficiency syndrome	2.65e-05	0.001	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL2—acquired immunodeficiency syndrome	2.62e-05	0.000991	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IFNA1—acquired immunodeficiency syndrome	2.61e-05	0.000989	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.61e-05	0.000987	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—IL6—acquired immunodeficiency syndrome	2.58e-05	0.000975	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	2.54e-05	0.000963	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD79A—acquired immunodeficiency syndrome	2.54e-05	0.00096	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.53e-05	0.000957	CbGpPWpGaD
Sirolimus—MTOR—Disease—CXCR4—acquired immunodeficiency syndrome	2.52e-05	0.000953	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	2.49e-05	0.000941	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.39e-05	0.000903	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.38e-05	0.0009	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.38e-05	0.0009	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.35e-05	0.00089	CbGpPWpGaD
Sirolimus—FGF2—Disease—CCR5—acquired immunodeficiency syndrome	2.33e-05	0.00088	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.16e-05	0.000818	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.15e-05	0.000814	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.07e-05	0.000785	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD40LG—acquired immunodeficiency syndrome	2.07e-05	0.000783	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.06e-05	0.00078	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD8A—acquired immunodeficiency syndrome	2.04e-05	0.000774	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CSF2—acquired immunodeficiency syndrome	2.04e-05	0.000774	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—IL6—acquired immunodeficiency syndrome	2.04e-05	0.000771	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CD4—acquired immunodeficiency syndrome	2.02e-05	0.000763	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.99e-05	0.000753	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-B—acquired immunodeficiency syndrome	1.97e-05	0.000744	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.94e-05	0.000733	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CD4—acquired immunodeficiency syndrome	1.93e-05	0.00073	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.91e-05	0.000723	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.89e-05	0.000716	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.88e-05	0.00071	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.81e-05	0.000684	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.78e-05	0.000674	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.76e-05	0.000668	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.76e-05	0.000668	CbGpPWpGaD
Sirolimus—MTOR—Disease—CCR5—acquired immunodeficiency syndrome	1.73e-05	0.000653	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.69e-05	0.000641	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.66e-05	0.00063	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IFNG—acquired immunodeficiency syndrome	1.64e-05	0.00062	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.63e-05	0.000617	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD4—acquired immunodeficiency syndrome	1.58e-05	0.000599	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.57e-05	0.000593	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL6—acquired immunodeficiency syndrome	1.54e-05	0.000583	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.47e-05	0.000556	CbGpPWpGaD
Sirolimus—FGF2—Disease—CD4—acquired immunodeficiency syndrome	1.46e-05	0.000553	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL2—acquired immunodeficiency syndrome	1.46e-05	0.000551	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.41e-05	0.000533	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.34e-05	0.000508	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.33e-05	0.000504	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.32e-05	0.0005	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.24e-05	0.00047	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IFNG—acquired immunodeficiency syndrome	1.22e-05	0.00046	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.21e-05	0.000458	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD4—acquired immunodeficiency syndrome	1.17e-05	0.000444	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.09e-05	0.000413	CbGpPWpGaD
Sirolimus—MTOR—Disease—CD4—acquired immunodeficiency syndrome	1.08e-05	0.00041	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL2—acquired immunodeficiency syndrome	1.08e-05	0.000409	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—acquired immunodeficiency syndrome	1.04e-05	0.000395	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.95e-06	0.000377	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	9.47e-06	0.000358	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.41e-06	0.000356	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ALB—acquired immunodeficiency syndrome	8.86e-06	0.000335	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—acquired immunodeficiency syndrome	8.56e-06	0.000324	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	8.13e-06	0.000308	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—acquired immunodeficiency syndrome	7.9e-06	0.000299	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.3e-06	0.000276	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.99e-06	0.000264	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—acquired immunodeficiency syndrome	6.35e-06	0.00024	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	5.88e-06	0.000222	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—acquired immunodeficiency syndrome	5.86e-06	0.000222	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.53e-06	0.000209	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	4.44e-06	0.000168	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.11e-06	0.000155	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	2.73e-06	0.000103	CbGpPWpGaD
